Corcept Therapeutics Incorporated stock performance trend indicates that the stock price has rallied 21.92% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 52.31% . Looking at the past 52 week period, the stock price is up at 127.59% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Corcept Therapeutics Incorporated has a positive value of 49.06 compared to overall market.Corcept Therapeutics Incorporated is having a Relative Strength Index of 58.43 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Corcept Therapeutics Incorporated (NASDAQ:CORT) has tumbled 8.92% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 19.35% in the last four weeks. The stocks have underperformed the S&P 500 by 9.14% during the past week but Corcept Therapeutics Incorporated (NASDAQ:CORT) it has outperformed the index in 4 weeks by 17.99%.
Company shares have received an average consensus rating of Hold for the current week Corcept Therapeutics Incorporated (NASDAQ:CORT) : On Friday heightened volatility was witnessed in Corcept Therapeutics Incorporated (NASDAQ:CORT) which led to swings in the share price. The stock opened for trading at $9.7 and hit $9.97 on the upside , eventually ending the session at $9.9, with a gain of 0.2% or 0.02 points. The heightened volatility saw the trading volume jump to 1,712,459 shares. The 52-week high of the share price is $11.4 and the company has a market cap of $1,118 million. The 52-week low of the share price is at $3.87 .
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Corcept Therapeutics Incorporated was Initiated by Ladenburg Thalmann on Feb 2, 2017 to Buy, Price Target of the shares are set at $14.
Company has reported several Insider transactions to the SEC, on Mar 15, 2017, Patrick G Enright (director) sold 600,000 shares at 10.46 per share price.On Mar 2, 2017, James N Wilson (director) sold 158,812 shares at 8.78 per share price.On Nov 14, 2016, David L Mahoney (director) sold 30,000 shares at 9.35 per share price.
Corcept Therapeutics Incorporated Last issued its quarterly earnings results on Jan 30, 2017. The company reported $0.02 EPS for the quarter. Analyst had a consensus estimate of $0.02. The company had revenue of $23.80 million for the quarter, compared to analysts expectations of $23.46 million. The companys revenue was up 59.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.01 EPS.
Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol. It is developing its lead product, CORLUX for the treatment of the psychotic features of psychotic major depression. Corcept Therapeutics Incorporated is headquartered in Menlo Park, California.